WHY IT MATTERS: Patients relying on tested and labeled cannabis products from New York dispensaries should check the OCM recall list to confirm their specific products are safe to use and return any flagged items to their point of purchase. CLINICAL OVERVIEW: Regulatory bodies like the New York State Office of Cannabis Management have the authority to issue precautionary recalls when questions arise about the accuracy or integrity of third-party laboratory testing, which serves as the primary safety checkpoint between cultivators and consumers. Cannabis testing laboratories are responsible for verifying potency, pesticide levels, heavy metals, residual solvents, and microbial contamination, and any uncertainty in those results can expose patients and consumers to unquantified risks.
Wisconsin: 47 Lawmakers File Bill to Legalize Marijuana, Create Regulated Market and … – Reddit
WHY IT MATTERS: If this bill passes in Wisconsin, patients who currently travel to neighboring states or use unregulated products could gain legal access to quality-tested cannabis under the guidance of their physicians. CLINICAL OVERVIEW: Wisconsin lawmakers have introduced a significant bipartisan bill with 47 co-sponsors to legalize marijuana, establish a regulated market, and expunge past cannabis convictions. From a clinical perspective, regulated legalization would give patients in Wisconsin legal access to tested, labeled cannabis products rather than relying on unregulated sources, while expungement provisions address the longstanding public health harms caused by criminalization.
Researcher: Remediated cannabis may still have harmful mold – MJBizDaily
WHY IT MATTERS: If you are using cannabis purchased from a dispensary, you should know that passing a state lab test does not guarantee your product is free from all harmful mold species, which is especially important if you have a weakened immune system or chronic lung conditions. CLINICAL OVERVIEW: Recent research highlights that cannabis products which have undergone remediation processes to address mold contamination may still harbor harmful fungal organisms that current state-mandated testing protocols fail to detect. This raises significant clinical concerns because immunocompromised patients and those with respiratory conditions may be unknowingly exposed to mycotoxins and viable mold spores, and the assumption that vaporization eliminates these contaminants appears to be unsupported by the evidence.